News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
kalkine.ca Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This page provides real-time stock information for Palatin Technologies Inc (PTN), a biotechnology and medical research company. It shows the current stock price, market cap, P/E ratio, and notes that more news and analysis will be available soon. The page is part of TradingKey, …
Palatin Technologies director John K.A. Prendergast was granted a stock option for 2,900 shares of common stock at an exercise price of $7.70 per share under the 2011 Stock Incentive Plan. The option vests 50% on August 3, 2027, and the remaining 50% on …
Palatin Technologies director Arlene Morris was granted 2,400 stock options with an exercise price of $7.70 per share. These options will vest 50% on August 3, 2027, and 50% on August 3, 2028, and are set to expire on August 3, 2037. This grant …
Palatin Technologies' shareholders approved key governance measures at their annual meeting, including electing four directors, ratifying KPMG as their accounting firm, and amending the 2011 Stock Incentive Plan to increase shares for equity awards. This indicates strong shareholder support for the company's leadership, audit …
Palatin Technologies, Inc. (NASDAQ: PTN) filed a Form 8-K detailing the outcomes of its annual stockholders' meeting held on July 28, 2026. Key resolutions included the election of directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and a potentially price-sensitive …
This article provides a historical overview of dividends and stock splits for Palatin Technologies Inc (PTN). It indicates that the company has not distributed any dividends in the past five years. However, it lists several stock split events that occurred on August 22, 2022, …
Palatin Technologies Inc (PTN) has a current risk assessment score of 1.94, placing it in the lower half of its industry for risk. The company's beta of 0.55 suggests it is less volatile than the S&P 500 benchmark, outperforming during downturns but underperforming during …
This article provides a technical analysis of Palatin Technologies Inc (PTN), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, PTN's current price momentum score is 5.14, ranking 110 out of 386 in …
Palatin Technologies Inc (PTN) experienced a 5.41% drop on July 24, 2026, closing at $7.60. Despite a weak market performance, analysts rate PTN as a "Buy" with a target price of $53.50, indicating significant upside potential. The biopharmaceutical company is developing first-in-class medicines targeting …
Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion, and Neurocrine Biosciences acquired Soleno Therapeutics for $2.9 billion, both for oral treatments of rare endocrine disorders. These acquisitions validate the commercial potential of oral therapies for rare conditions like hyperphagia and acromegaly. Palatin Technologies, …
Palatin Technologies (PTN) stock is trading quietly after reporting stabilized revenue and a narrowed net loss for fiscal year 2025. The biotech company saw its total revenue increase to $16.3 million from $10.4 million in FY 2024, primarily driven by sales of its lead …
Carl Spana, President and CEO of Palatin Technologies (PTN), reported three F-code transactions on July 15, 2026, involving the withholding of 294 common shares by the issuer. These shares, valued at $14.34, $11.72, and $11.77 per share, were used to satisfy employee withholding taxes …
Search by ticker symbol or company name and select a result to open its chart.